Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2017 Feb 22;7:41904. doi: 10.1038/srep41904

Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle

Kaizong Huang 1,2, Ningjun Duan 1, Chunmei Zhang 1, Ran Mo 2, Zichun Hua 1,2,3,4,a
PMCID: PMC5320504  PMID: 28225020

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been known as a promising agent for cancer therapy due to its specific apoptosis-inducing effect on tumor cells rather than most normal cells. However, systemically delivered TRAIL suffers from a rapid clearance from the body with an extremely short half-life. Thermally responsive elastin-like polypeptides (ELPs) are a promising class of temperature sensitive biopolymers based on the structural motif found in mammalian tropoelastin and retain the advantages of polymeric drug delivery systems. We therefore expressed RGD-TRAIL fused with ELP (RGD-TRAIL-ELP) in E. coli. Purification of RGD-TRAIL-ELP was achieved by the conveniently inverse transition cycling (ITC). The purified RGD-TRAIL-ELP without any chemical conjugation was able to self-assemble into nanoparticle under physiological condition. Non-reducing SDS-PAGE results showed that trimer content of RGD-TRAIL-ELP increased 3.4-fold than RGD-TRAIL. Flow cytometry confirmed that RGD-TRAIL-ELP 3-fold enhanced apoptosis-inducing capacity than RGD-TRAIL. Single intraperitoneal injection of the RGD-TRAIL-ELP nanoparticle induced nearly complete tumor regression in the COLO-205 tumor xenograft model. Histological observation confirmed that RGD-TRAIL-ELP induced significant tumor cell apoptosis without apparent liver toxicity. These findings suggested that a great potential application of the RGD-TRAIL-ELP nanoparticle system as a safe and efficient delivery strategy for cancer therapy.

The tumor necrosis factor (TNF) family comprises several ligands, such as the prototype TNF-α, the Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL), which trigger apoptosis in susceptible cells by activating respective cell-surface receptors1,2. However, TRAIL possesses some notable differences from TNF-α and FasL. TNF-α and FasL activate similar pathways using the same signaling proteins but present unacceptable side effect when administered systemically3. For example, TNF-α stimulates proliferation, survival, migration, and angiogenesis in most cancer cells, resulting in tumor promotion4; some study demonstrated that upregulation of FasL expression by tumor cells may enable the tumor cells to kill antitumor immune effector cells by activating lymphocytes express Fas5. At the other hand, TRAIL exhibits much stronger apoptotic activity than other TNF family members, kills tumor cells more effectively than normal cells, and is unlikely to initiate inflammatory cascades following systemic administration. These unique features of TRAIL have attracted considerable attention on TRAIL as a potential therapeutic to treat human cancers6,7,8,9. Despite its great advantages and potency in cancer treatment, TRAIL has a short biological half-life in body and suffers from a rapid kidney clearance when systemically administered10,11.

To address this dilemma, a variety of strategies aiming to increasing TRAIL particles have been employed to significantly improve its circulating time in vivo, because the size of therapeutic agents significantly affects their circulation time in the blood stream12. The diameter is inversely related to renal clearance. Some study demonstrated that particles with a diameter smaller than 5–6 nm are rapidly cleared by the kidney (blood half-life <600 min), while increasing in particle diameter can significantly enhance the half-life of these agents in the blood and body12. Previous, some study demonstrated that TRAIL was rapidly cleared from the systemic circulation and had a short biological half-life (20 min)13. Improving pharmacodynamics and enhancing anti-tumor activity could obtain reasonable supporting from adding TRAIL to larger particles, such using liposomes conjugated with TRAIL14,15 or adding TRAIL to human serum albumin (HSA) nanopartilce16. However, TRAIL that was modified with HSA nanoparticle must be prepared in organic solvents and scale-up preparation of the fusion protein was limited16,17. Some researchers showed that PEGylated TRAIL could preserve the biological activity of TRAIL and exhibited a remarkably improved pharmacokinetic profile. On the other hand, the PEGylated drug encountered the accelerated blood clearance (ABC) phenomenon and lose the long-circulating behaviors after repeated systemic injection18,19. Many attempts had been made to optimize the therapeutic efficacy by encapsulating TRAIL into liposomes or poly (lactic-co-glycolic acid) (PLGA), which could sustain the release of TRAIL from these carriers and reduce the frequency of systemic administration. Unfortunately, several problems associated with microsphere fabrication and agent release system occurred, such as exposure of the protein to an aqueous organic interface, freeze-drying, and physical instability in non-physiological microenvironment20,21,22. In addition, release of TRAIL from these carriers remains a challenge23.

Elastin-like polypeptides (ELPs) are biopolymers consisting of repeated peptide sequence VPGXG (derived from human tropoelastin24. ELPs can be encoded in the gene level, which allows a precise control over biopolymer composition and molecular weight and can be rapidly purified by inverse transition cycling (ITC)25. Furthermore, ELPs could self-assemble into nanoparticle when heated to relevant temperature26. As an attractive drug carrier, ELPs are biodegradable and nontoxic as well as capable of improving the systemic circulation and biodistribution27. These merits of ELPs provide a greatly promising application in drug delivery25,28. For example, ELP fusion protein for applications in diabetes treatment has been studied on phase II clinical trial.

We had demonstrated that RGD-TRAIL had a higher affinity with some cancer cells and showed enhanced therapeutic efficacy in suppressing tumor growth of the human colon carcinoma (COLO-205) tumor-bearing mice, compared to free TRAIL with the equivalent dose29. Nevertheless, RGD-TRAIL with small size also displayed short systemic circulation in vivo. Additionally, the existence of five cysteine residues and disulfide bond in RGD-TRAIL indicated that the soluble RGD-TRAIL was hardly achieved from E. coli.

Previously, our result had shown RGD-TRAIL fused with ELP (ELP [V5-60]) can be rapidly purified by ITC, improve apoptosis activity and self-assemble into microparticle. RGD-TRAIL fused with ELP (ELP [V5-60] would aggregate at 30 °C (5 μM)30. Accordingly, to optimize design, the RGD-TRAIL fused with relatively hydrophilic ELP (ELP [VH4-40]). Taking advantage of aggregative character of ELP, the polypeptide (RGD-TRAIL-ELP) was expected to be rapidly purified, formed more trimer and was able to self-assemble into nanoparticle under physiological condition (37 °C). Furthermore, due to increasing to diameter, once administrated to mice, RGD-TRAIL-ELP nanoparticle was suggested to improve the systemic circulation, generate more accumulation and elevate antitumor activity (Fig. 1).

Figure 1. Schematic illustration of the RGD-TRAIL-ELP nanoparticle for tumor-targeted delivery.

Figure 1

Open in a new tab

Before administration, the RGD-TRAIL-ELP was heated to the temperature of 37 °C to form nanoparticles (a); RGD-TRAIL-ELP was administered by i.p (b) and deposited in tumor site (c).

Our result suggested RGD-TRAIL delivery system was better than free TRAIL in vitro and vivo22, therefore, we took RGD-TRAIL as control in following experiments.

Results

RGD-TRAIL-ELP expression and purification

The RGD-TRAIL-ELP recombinant proteins were successfully expressed in a soluble form and the final yield was about 20 mg/L. RGD-TRAIL-ELP was then analyzed by non-reducing and reducing SDS-PAGE. The reducing SDS-PAGE of RGD-TRAIL-ELP showed a single band of 37 kDa, consistent with the expected molecular weight (Fig. 2a). TNF family ligands, like TRAIL, can appear as monomer, dimer, and trimer forms. RGD-TRAIL-ELP also existed as a multimer form (Fig. 2b). Maldi-TOF (Fig. 2e) yielded a MW of 37087, 74168, 111252 Da, pointed to monomeric, dimeric and trimeric RGD-TRAIL-ELP. According to Fig. 2, it was estimated that 38% of RGD-TRAIL-ELP or 12% of RGD-TRAIL formed trimer respectively (Fig. 2b,d)29. Therefore, fusing ELPs chimeric polypeptide could contribute to form more multimers of TRAIL fusion protein.

Figure 2. RGD-TRAIL-ELP were analyzed under nonreducing (−DTT, Fig. 2a) and reducing (+DTT, Fig. 2a) conditions by PAGE; RGD-TRAIL (lane 1) and ELP (lane 2) were analyzed under (+DTT, Fig. 2c) and reducing nonreducing (−DTT, Fig. 2d) conditions by PAGE; Maldi-TOF analyzed RGD-TRAIL-ELP (Fig. 2e).

Figure 2

Open in a new tab

Characterization of the RGD-TRAIL-ELP nanoparticle

As demonstrated in Fig. 3a, RGD-TRAIL-ELP began to aggregate near 40 °C. According to ref. 31, transition temperature was defined as the solution temperature at the maximum of the turbidity gradient, we estimated that transition temperature was 44 °C at concentration of 500 μg/ml17.

Figure 3. Characterization of RGD-TRAIL-ELP.

Figure 3

Open in a new tab

Turbidity (a) and hydrodynamic diameter (b) profiles for RGD-TRAIL-ELP across range temperature at a concentration of 500 μg/ml in PBS; Freeze-fracture TEM images of RGD-TRAIL (c) and RGD-TRAIL-ELP (d, at 10 °C; e, at 37 °C); photographic image of RGD-TRAIL-ELP prepared at 10 and 37 °C (f).

Figure 3a demonstrated that hydrodynamic diameter dramatically increased at 40 °C, which is consistent with the transition temperature result that significant aggregation was observed near 40 °C. The average diameter of RGD-TRAIL-ELP reached to ~190 nm at 37 °C (Fig. 3b and Supplementary Fig. S1). In sharp contrast, RGD-TRAIL itself only had the diameter around 8 nm regardless of the temperature (Fig. 3c). It is suggested that ELP motif greatly enhanced RGD-TRAIL’s propensity towards aggregation or assembly in response to the surrounding temperature. Additionally, the size of the RGD-TRAIL-ELP (37 °C) nanoparticle determined from the freeze fracture TEM (Fig. 3e) images was in agreement with that obtained from the DLS measurement.

Biological activity

To compare the biological activity of RGD-TRAIL and RGD-TRAIL-ELP in vitro, we monitored caspase cleavage following treatments by two TRAIL variants because caspases were proportional to the potency of the TRAIL5. Treatment with RGD-TRAIL resulted in cleavage of procaspases 8, 9 and 3, but significant amounts of procaspases remained after 1 h of treatment. In comparison, more rapid cleavage of cellular procaspase was detected and most of procaspases disappeared by 2 h when after RGD-TRAIL-ELP treatment (Fig. 4). These data verified higher potency of RGD-TRAIL-ELP in apoptosis induction than RGD-TRAIL.

Figure 4. Western blot analysis of procaspase cleavage levels after COLO-205 cells were exposed to RGD-TRAIL and RGD-TRAIL-ELP over time (0, 0.25, 0.5, 1, 2 h).

Figure 4

Open in a new tab

procaspase 8 (a, RGD-TRAIL; b, RGD-TRAIL-ELP); procaspase 9 (d, RGD-TRAIL; e, RGD-TRAIL-ELP); procaspase 3 (g, RGD-TRAIL; h, RGD-TRAIL-ELP). Densitometric analysis of procaspase cleavage levels, relative content was obtained from the densitometry that the given time over the zero time, procaspase 8 (c); procaspase 9 (f); procaspase 3 (i).

We also investigated the biological activity of RGD-TRAIL-ELP. After treatment with serial dilutions of RGD-TRAIL and RGD-TRAIL-ELP, COLO-205 cells were stained with annexin V-FITC and PI, followed by flow cytometry analysis (Fig. 5). The half maximal effective concentration (EC50) for inducing 50% apoptosis of RGD-TRAIL and RGD-TRAIL-ELP was 1 and 0.35 nM (20.57 and 13.61 ng/ml), respectively, which suggest that RGD-TRAIL-ELP had a 3-fold enhanced apoptosis-inducing capacity than RGD-TRAIL. The elevated apoptosis-inducing capacity of RGD-TRAIL-ELP may be attributed to fact that the more homomultimer formed by RGD-TRAIL-ELP8, compared to less trimer formed by RGD-TRAIL that was reported in our previous work29. On the other hand, endothelial cells did not show apparent apoptosis by treating with RGD-TRAIL-ELP or RGD-TRAIL(500 ng/ml, Supplementary Fig. S2)

Figure 5.

Figure 5

Open in a new tab

Dose-dependent apoptosis-inducing effect of RGD-TRAIL and RGD-TRAIL-ELP on COLO-205 cells (a); effect of RGD-TRAIL and RGD-TRAIL-ELP at different concentrations on COLO-205 cell death and apoptosis as determined by FACS using the Annexin V-FITC/PI staining (b).

Tumor accumulating capability

The tumor accumulation of different formulations in the COLO-205 tumor-bearing nude mice was evaluated after intravenous injection over time by near infrared spectroscopy. Representative images were shown in Supplementary Fig. S3. RGD-TRAIL exhibited rapid tumor-targeting capability in time-dependent property. As time lapsed, the fluorescence signals of Cy5.5-RGD-TRAIL waned at the tumor site and gradually increased in the liver. These results indicated that RGD-TRAIL presented a higher tumor-binding ability and might eventually degrade in the liver29,32.

In view of ELP, a high concentration of Cy5.5-ELP was primarily detected but was relatively faint in the tumor region over time. It is noteworthy that most of Cy5.5-ELP has been cleared from body followed by a further steady movement and was excreted by the renal pathway judged by the strong signals in bladder.

Cy5.5-RGD-TRAIL-ELP showed no remarkable intense fluorescence signal in the region of tumor within 2 h post-injection. As time extended, increased fluorescence signal of Cy5.5-RGD-TRAIL-ELP was observed at the tumor site compared with that at the normal tissues, suggesting superior ability of RGD-TRAIL-ELP to accumulate at tumor sites. Interestingly, after 24 h injection, the significant fluorescence accumulation was observed at the site of tumor and the scarce fluorescence signal was detected in other parts of body.

At 24 h post-administration, the mice were immediately euthanized. The tumors and normal tissues were harvested for ex vivo imaging. As expected, for the RGD-TRAIL and ELP groups, only a small deposition of fluorescence was detected in the tumor, while a higher intensity of fluorescence signal was detected in the liver and kidney. RGD-TRAIL indeed displayed a relatively higher tumor-specificity than ELP control protein (Fig. 6). In the RGD-TRAIL-ELP group, a greater amount of fluorescence was enriched in the tumor, which was 2.5-fold higher than that in the RGD-TRAIL group; other tissues, such as heart, liver, spleen, lung and kidney, presented relatively weaker intensity, which further confirmed the tumor oriented accumulation of RGD-TRAIL-ELP. The selected target-to-background ratios were further determined by comparing the fluorescence intensity of Cy5.5 at the tumor to that at normal tissues in each studied group (Fig. 6c and Table 1). It is confirmed that the RGD-TRAIL-ELP nanoparticle presented a stronger capability of selective accumulation at the tumor tissue than either RGD-TRAIL or ELP.

Figure 6.

Figure 6

Open in a new tab

Ex vivo fluorescence imaging of the tumor and normal tissues harvested from the euthanized COLO-205 tumor-bearing nude mice at 24 h post injection of different Cy5.5-labeled formulations (a); quantification of fluorescent signal intensities of excised organs from mice at 24 h post injection. The data were recorded as total photons per centimeter squared per steradian (p/s/cm2/sr) (b); the selected target-to-accumulating background ratios of each studied group (c). **P < 0.01.

Table 1. Biodistribution of organs after 24 hours.

Tumor Liver Lung Heart Spleen Kindey
44% 18% 8% 6% 10% 14%
Open in a new tab

To verify the accumulation of RGD-TRAIL or RGD-TRAIL-ELP at the tumor site by i.p. administration, tumor tissues were obtained four days after treatment. The distribution of RGD-TRAIL or RGD-TRAIL-ELP in the tumor tissue was analyzed using the immunofluorescence staining. In the RGD-TRAIL-ELP group, much stronger intensity of the fluorescence signal was detected, compared to another group (Supplementary Fig. S4). These results further indicated that the self-assembled RGD-TRAIL-ELP nanoparticle also showed more accumulation than the RGD-TRAIL in the tumor tissue by i.p. administration.

In vivo pharmacokinetics

As shown in Supplementary Fig. S5 and summarized in Table 2, substantial differences were observed between the plasma pharmacokinetics of RGD-TRAIL and RGD-TRAIL-ELP. The half-life of RGD-TRAIL-ELP was 4.5 fold higher than that of RGD-TRAIL alone. The area under the curve from zero to infinity of RGD-TRAIL-ELP was 2.9 fold greater than that of RGD-TRAIL, and the plasma clearance of RGD-TRAIL-ELP was only 0.26 mL/min.

Table 2. Comparing of pharmacokinetic parameter after adminstration RGD-TRAIL or RGD-TRAIL-ELP to rat at 100 μg (0.5 mg/kg) i.v, n = 4.

Pharmacokinetic parameter RGD-TRAIL RGD-TRAIL-ELP
ACUinfa (ng·min/ml) 139623.75 ± 26170.08 402790 ± 41932.57
T1/2b (min) 50.87 ± 9.14 230.05 ± 11.42
CLc (ml/min) 0.94 ± 0.15 0.26 ± 0.026
Open in a new tab

aACUinf: Area under the curve from zero to infinity.

bT1/2: Half-life.

cCL: Clearance.

In vivo antitumor efficacy

The in vivo anti-tumor efficacy of RGD-TRAIL and RGD-TRAIL-ELP was evaluated in the COLO-205 tumor-bearing mice (Fig. 7 and Supplementary Fig. S6). Single administration of RGD-TRAIL and RGD-TRAIL-ELP were compared. Treatment with RGD-TRAIL at a dose of 1.5 mg/kg/day showed a slight response to the tumor compared with the PBS control. In contrast, treatment with the equimolar RGD-TRAIL-ELP (2.75 mg/kg/day) significantly inhibited the tumor growth. Furthermore, RGD-TRAIL-ELP at such dose achieved a higher tumor suppression effect than RGD-TRAIL at a high dose of 4.5 mg/kg/day. Co-delivery of RGD-TRAIL with free ELP showed unconspicuous antitumor effect than treatment with RGD-TRAIL at the same dose of 4.5 mg/kg/day. Notably, abolished tumors after injection day 10 was observed in the tumor-bearing mice treated with RGD-TRAIL-ELP at a higher dose of 8.25 mg/kg/day.

Figure 7. Change in the tumor size of the COLO-205tumor-bearing mice after treated with RGD-TRAIL or RGD-TRAIL-ELP.

Figure 7

Open in a new tab

*P < 0.05, **P < 0.01.

Tissue staining and histological analysis

An evaluation of apoptosis using the TUNEL assay revealed the clear presence of DNA fragmentation during apoptotic nuclei in the tumors of the mice after treated with RGD-TRAIL or RGD-TRAIL-ELP (Fig. 8). Greater amounts of tumor cell destruction were observed in the samples of RGD-TRAIL (4.5 mg/kg/day) or that plus free ELP, but apoptosis cells were rarely detected at lower dose (1.5 mg/kg/day) of the RGD-TRAIL group. Compared to the RGD-TRAIL groups, a larger amount of apoptotic cells were observed in the tumor tissues from the mice after treated with RGD-TRAIL-ELP, which resulted probably from a combination between the enhanced delivery efficiency of the nanoparticle and the bioactivity of RGD-TRAIL-ELP.

Figure 8. Confocal images of the tumor section obtained from the tumor-bearing mice after treatment with different formulations using the TUNEL staining (apoptotic and necrotic cells are shown in red) (×400).

Figure 8

Open in a new tab

To confirm the in vivo therapeutic effects of RGD-TRAIL-ELP, histological detection was also performed (Supplementary Fig. S7). Similar to the TUNEL staining result, treatment with RGD-TRAIL-ELP markedly increased the number of apoptotic cells, which further supported the superior antitumor efficacy of RGD-TRAIL-ELP in vivo.

The liver cytotoxicities of RGD-TRAIL and RGD-TRAIL-ELP were also evaluated using histological detection, respectively (Supplementary Fig. S8). RGD-TRAIL and RGD-TRAIL-ELP did not show any noticeable toxicity toward the murine liver cells. No significant variation in the body weight and parameter of toxicity in the kidneys during the treatment of both RGD-TRAIL and RGD-TRAIL-ELP also suggested the absence of serious toxic side effects (Supplementary Figs S9 and S10).

Discussion

Up to now, many recombinant versions of TRAIL had been purified from E. coli. Unfortunately, most of recombinant TRAILs were produced as inclusion bodies in E. coli33,34. Inclusion bodies should be solubilized and refolded, which would be restricted in industrial preparation. One strategy to overcome this issue is to fuse peptide tags to TRAIL. For example, TRAIL fused with leucine zipper35, polyhistidine-tag36 or immunoglobulin Fc domain37 could improve its solubility and bioactivity, but the purification process is indispensably performed by complicated affinity chromatography that required time-, cost- and labor-consuming efforts. To improve the biological half-life of TRAIL, covalent conjugating TRAIL with PEG was utilized23,38,39,40. However, the possibility of introducing more issues by adding a long ‘tail’ to the monomer would bring about some issues, such as affecting trimerization, receptor-binding or molecular flexibility of TRAIL41, it was reported that the half maximal inhibitory concentration (IC50) of the PEGylated TRAIL was 4.2-fold higher than that of TRAIL alone42. Moreover, these carriers are hard to modulate property and the purification and linking TRAIL cannot be realized in just one step43.

Based on our preparation techniques, we expressed soluble RGD-TRAIL-ELP fusion protein, which could be easily and rapidly purified from E. coil by ITC. The ITC purification method is an economical and convenient procedure, which is also easy to scale-up44. Additionally, RGD-TRAIL-ELP can significantly improve apoptosis-inducing bioactivity by forming more homotrimers. More importantly, the fusion polypeptide can self-assemble into nanoparticle under physiological condition. Such integration of purification and self-assembly into a uniform nanoparticle in one step can efficiently avoid the structural disruption of TRAIL and facilitate the formation of stable TRAIL multimer.

As a genetically-encoded amphiphilic polypeptide, ELP or its fusion protein can self-assemble into nanoparticle for drug delivery45. Below the transition temperature, ELP exists as a soluble monomer; when the temperature is raised above the transition temperature, the selective dehydration of ELP would become hydrophobic and therefore drive the self-assembly of ELP into a higher ordered hydrophobic core46,47. Previously, we described RGD-TRAIL delivery system for cancer therapy22. In the present study, we found that RGD-TRAIL fused to the ELP chimeric polypeptide displayed self-assembled property at 37 °C, and could contribute to form more multimers. Western blot also indicated that RGD-TRAIL-ELP triggered more efficient cleavage of caspases.

Most TRAILs are rapidly excreted by kidney, which results in a very short half-life and detracts the pharmaceutical application of TRAIL23. To address this issue, we enlarged the RGD-TRAIL size by taking advantage of the self-assembly property of ELPs, since the particle size is an important parameter impacting the fate of systemic delivery48. The self-assembly process of RGD-TRAIL-ELP at the body temperature was demonstrated by both the DLS measurement and the FF-TEM images. The RGD-TRAIL-ELP nanoparticle had a longer retention time in the blood circulation, reduced the clearance rate, and showed preference to accumulate at the tumor sites, compared with the RGD-TRAIL. Furthermore, the in vivo antitumor activity studies confirmed that the RGD-TRAIL-ELP nanoparticle produced an expected higher therapeutic efficacy than the RGD-TRAIL. This effect was further substantiated by both TUNEL and H&E assays. More importantly, RGD-TRAIL-ELP induced nearly complete tumor regression without acute liver toxicity and notable change in the body weights after treating the tumor-bearing mice at a dose of 8.25 mg/kg/day.

In summary, we had successfully expressed and rapidly purified RGD-TRAIL-ELP by ITC, RGD-TRAIL-ELP could form more multimers and presented an enhanced apoptosis-inducing capability. Noteworthiness, RGD-TRAIL-ELP could self-assemble into nanoparticle under physiological conditions (pH 7.4, 37 °C), the size of which could be adjusted by the environmental temperature. The RGD-TRAIL-ELP nanoparticle system accomplished a much better bioavailability and significantly improved antitumor effect than the RGD-TRAIL solution in vivo. In addition, no evident sign of toxic effect on the liver was observed during the RGD-TRAIL-ELP treatment. Taken together, the admirable properties of RGD-TRAIL-ELP could offer a safe and attractive strategy for the application of the protein-based delivery system to treat cancer.

Methods

Statement

All experiments in current study were performed in accordance with relevant guidelines and regulations.

Animals

Female nude mice (5–6 weeks old, ~20 g) were obtained from Academy of Chinese Military Medical Sciences. This experiment was approved by the Animal Ethics Committees of the Institute of Materia Medica, Chinese Academy of Medical Sciences and Nanjing University. Animals were maintained in a pathogen-free environment (23 ± 2 °C and 55 ± 5% humidity) through a 12 h light ~12 h dark cycle with food and water supplied across the experimental period. The animals were housed and cared for in accordance with the guidelines established by the National Science Council of Republic of China.

ELP cloning, expression and purification

The oligonucleotides ELP [VH4-5] were synthesized by Genscrips (Nanjing China). ELP [VH4-40] was constructed using plasmid reconstruction recursive directional ligation49. ELP [VH4]-40 contained 8 monomeric ELP pentapeptides ELP[VH4-5], which has a repeat unit composed of 5 pentapeptides with the guest residues Val and His in 1:4 ratio50. ELP [VH4-40] was cloned into the modified pET-23a-RGD-TRAIL (BamHI and XhoI), the vector was named as pET-23a-RGD-TRAIL-ELP and correct clones were identified by DNA sequencing. RGD-TRAIL-ELP was expressed and purified by employing ITC51. In brief, one round of ITC is described as follows: (1) the RGD-TRAIL-ELP solution with sodium chloride was supplemented to a final concentration of ~1 M; (2) the solution was heated to the temperature of 37 °C to initiate the inverse phase transition; (3) centrifugation at 12,000 rpm to collect RGD-TRAIL-ELP at 37 °C; (4) the RGD-TRAIL-ELP pellet was resuspended in cold PBS at 4 °C; (5) the insoluble debris was removed by centrifugation at 13000 rpm 4 °C. The purified protein was achieved by three rounds of ITC and passed through a 10 mL of bed high-capacity endotoxin removal resin (Thermo Scientific).

Protein analysis

Protein electrophoresis of purified TRAIL- ELP was performed under reducing (+DTT) and non-reducing (−DTT) conditions using Coomassie blue staining29. Maldi-TOF was performed to further analysis molecular weight of RGD-TRAIL-ELP.

Characterization of nanoparticle

The transition temperature of RGD-TRAIL-ELP was calculated by recording the optical density at 350 nm as a function of temperature (1 °C/min) on a temperature controlled spectropolarimete J-815 (Jasco: Tokyo, Japan) equipped with a multicell thermoelectric temperature controller between 25 and 60 °C.

Dynamic light scattering (DLS) measurement was used to determine the particle radius of the RGD-TRAIL-ELP nanoparticle. Before measurement, RGD-TRAIL-ELP was filtered through a membrane filter with 0.1 μm size pores at 4 °C and was adjust to 500 μg/mL in phosphate buffered solution (PBS). Average size and size distribution of the RGD-TRAIL-ELP nanoparticles were then characterized using Dynamic Light Scattering (DLS; DynaPro Plate Reader, Wyatt Technology) over a range of temperature. The light scattering data were analyzed using a regularization fit and the Rayleigh spheres algorithm. Aberrant peaks were only eliminated if they accounted for less than 2% of the sample by mass.

The transmission electron microscope (TEM) characterization on the morphology of the RGD-TRAIL-ELP nanoparticle was performed by freeze fracture replication according to standard techniques24. Briefly, samples were heated to the temperature of 37 °C and rapidly cooled using the liquid nitrogen-cooled propane. The obtained samples were fractured by using a Leica EM VCT100 and the faces were coated with platinum at an angle of 30°. This process formed a replica of the fractured surface that was further cleaned with nitric acid prior to imaging28. The surface morphology of the RGD-TRAIL-ELP nanoparticle was via transmission electron microscope (JEM2100EX electron microscope, JEOL, Japan).

Apoptosis assessment by Annexin V-FITC/propidume iodide (PI) staining and Western blot

COLO 205 cells were cultured in RPMI 1640, supplemented with 10% fetal bovine serum at 37 °C and 5% CO2 atmosphere.

To elucidate distinction in the activity between RGD-TRAIL and RGD-TRAIL-ELP, COLO-205 cells were exposed to 100 ng/ml RGD-TRAIL or RGD-TRAIL-ELP, and harvested at prearranged time interval. Procaspases 8, 9 and 3 were analyzed and compared by Western blot8.

To further determine the apoptotic activities of RGD-TRAIL and RGD-TRAIL-ELP, COLO 205 cells (106 cells) were treated with RGD-TRAIL-ELP and RGD-TRAIL at range concentrations. The cells were harvested and washed with PBS thrice. Cell apoptosis and necrosis were analyzed using the Annexin V-FITC/PI staining as described previously29.

Synthesis of Cy5.5-labeled recombinant protein

Cy5.5-labeled RGD-TRAIL (Cy5.5-RGD-TRAIL) and RGD-TRAIL-ELP (Cy5.5-RGD-TRAIL-ELP) were synthesized by reacting with the Cy5.5–NHS ester. For ELP, 5 lysine residues that were conjugated with Cy5.5 were introduced into the ELP sequence. Cy5.5-labeled recombinant protein was prepared as described previously in ref. 52. In brief, Cy5.5, SE (1 mg, 8.86 μM) was dissolved in 100 μL of dmethyl sulphoxide (DMSO). RGD-TRAIL, ELP and RGD-TRAIL-ELP were dissolved in 500 μL of 50 mM NaHCO3 (pH 8.5) and then mixed with Cy5.5, SE ([Cy5.5, SE]/[-NH2] = 5). After overnight incubation at 4 °C in dark, RGD-TRAIL-ELP and RGD-TRAIL were purified by dialysis against water in dark for 48 h at room temperature and the water was exchanged several times. Afterward, the solution was ultrafiltrated and concentrated using a centrifugal filter. The fluorescence spectra of the obtained Cy5.5-RGD-TRAIL and Cy5.5-RGD-TRAIL-ELP were measured using a fluorescence spectrophotometer (Shimadzu, Japan).

In vivo real-time imaging

Female athymic nude mice bearing a subcutaneously COLO-205 tumor (approximately 350~500 mm3) were intravenously injected with Cy5.5-labeled RGD-TRAIL and Cy5.5-RGD-TRAIL-ELP at a dosage of 5 mg/kg (100 μg). In vivo fluorescence imaging was performed by scanning the mouse abdomen at the predetermined time interval (2, 4, 8, 24 h) using IVIS Lumina XR system (Caliper, Life science) with Cy5.5 excitation (640 nm) and emission (672 nm) filter sets. At 24 h post injection, the mice were sacrificed. Their major organs and tumor were harvested. Each organ and tumor were rinsed with saline three times and put into the board. To analyze the organ distribution, all data are calculated using the region-of-interest (ROI) function of analysis workstation software and data were given as mean ± S.D. for a group of three animals. A quantification of fluorescence signals was performed as total photons per centimeter squared per steradian (p/s/cm2/sr) per each organs and tumor.

In vivo pharmacokinetics

The pharmacokinetic profiles of RGD-TRAIL and RGD-TRAIL-ELP were examined by intravenous administration. Plasma samples were obtained at different time points by centrifugation and stored at −20 °C until required for assay. The RGD-TRAIL and RGD-TRAIL-ELP concentration in serum were determined by using ELISA kits according to manufacturer’s instructions. Kinetica4.4 software was used to calculate pharmacokinetic parameters.

In vivo antitumor efficacy

Evaluation of antitumor activity with a xenografted mice model was carried out as described previously. Briefly, 2.5 × 106 of COLO-205 cells were resuspended in 100 μL of PBS, and subcutaneously implanted into the right flank region of the female BALB/c nu/nu mice. Treatment was initiated when the tumors reached a mean volume of ~100 mm3 (Eight days after tumor implantation). Before administration, the RGD-TRAIL-ELP was heated to the temperature of 37 °C to form nanoparticles. 1.5 or 4.5 mg/kg/day RGD-TRAIL or RGD-TRAIL-ELP (2.75 mg/kg/day or 8.25 mg/kg/day) were administered by i.p. injection for 14 days. Free ELP (3.75 mg/kg/day) plus RGD-TRAIL (4.5 mg/kg/day) was also injected by i.p. Tumor volumes were monitored every other day. Six groups were defined (n = 5). Mice were cared for in accordance with the guide for the care and use of laboratory animals. Tumors were measured with a caliper, and the tumor volume was calculated as width2 × length × 0.5.

Tissue staining and histological analysis

The subcutaneous dorsa of female BALB/c nu/nu mice (6 weeks old) were inoculated with 2.5 × 106 COLO-205 cells. To test targeting study by i.p. injection mice were randomly divided into six groups (n = 3) when the tumors reached ~100 mm2, and was administered i.p. Four days after treatment, tumor and liver were harvested, fixed in 4% paraformaldehyde, and embedded in paraffin and sectioned (5-μm thick). The tumor and liver sections were stained with hematoxylin and eosin (H&E), and observed by an optical microscope (Eclipse, E100, Nikon, Japan). Apoptotic cells in tumor tissues were assessed with the DAPI staining and terminal deoxynucleotidyl transferasemediated nick end labeling (TUNEL) assays with commercial apoptosis detection kit (Vazyme Corp., Nanjing). Samples were visualized by a confocal microscope (Nikon confocal microscope, C2+, Nikon, Tokyo).

For immunofluorescence, tumor tissue sections were incubated with fluorescein isothiocyanate (FITC)-conjugated secondary antibody (diluted 1:500 in PBS) for 60 min at room temperature. The tumor sections were then washed with PBS, incubated with DAPI (to stain nuclei), slide-mounted, and sealed. Localization of TRAIL (Rabbit mAb, Cell Signaling Technology) in tumor tissue was visualized using the confocal microscope53.

Data analysis

All experiments were performed three times and data was expressed as the mean ± s.d. (n = 3). The significance of difference was determined using the Student’s t-test. P-values of <0.05 and <0.01 were considered as statistical significance and extreme significance, respectively.

Additional Information

How to cite this article: Huang, K. et al. Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle. Sci. Rep. 7, 41904; doi: 10.1038/srep41904 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supplementary Information
srep41904-s1.doc (3.4MB, doc)

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81630092, 81421091), National Key Research Project (2016YFC0902700, 2014CB744501), Shenzhen Science and Technology Innovation Committee (JCYJ20160331152141936) and Shenzhen Peacock Plan (KQTD20140630165057031).

Footnotes

The authors declare no competing financial interests.

Author Contributions K.Z.H. designed and performed most experiments and data analysis. N.J.D. and C.M.Z. purified protein and performed animal experiments. R.M. and C. Zhang joined the discussion of this manuscript. Z.C.H. designed and directed the overall project, and wrote the manuscript.

References

  1. Pan G. H. et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815–818, doi: 10.1126/science.277.5327.815 (1997). [DOI] [PubMed] [Google Scholar]
  2. Pan G. H. et al. The receptor for the cytotoxic ligand TRAIL. Science 276, 111–113, doi: 10.1126/science.276.5309.111 (1997). [DOI] [PubMed] [Google Scholar]
  3. Thorburn A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J Thorac Oncol 2, 461–465, doi: 10.1097/JTO.0b013e31805fea64 (2007). [DOI] [PubMed] [Google Scholar]
  4. Wang X. & Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta pharmacologica Sinica 29, 1275–1288, doi: 10.1111/j.1745-7254.2008.00889.x (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Houston A. et al. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. International journal of cancer 107, 209–214, doi: 10.1002/ijc.11392 (2003). [DOI] [PubMed] [Google Scholar]
  6. Curnis F., Gasparri A., Sacchi A., Longhi R. & Corti A. Coupling tumor necrosis factor-alpha with alpha(v) integrin ligands improves its antineoplastic activity. Cancer Res 64, 565–571, doi: 10.1158/0008-5472.Can-03-1753 (2004). [DOI] [PubMed] [Google Scholar]
  7. Huang Y., Erdmann N., Peng H., Zhao Y. & Zheng J. L. The Role of TNF Related Apoptosis-Inducing Ligand in Neurodegenerative Diseases. Cell Mol Immunol 2, 113–122 (2005). [PubMed] [Google Scholar]
  8. Kim S. H. et al. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human Esophageal epithelial cells. J Biol Chem 279, 40044–40052, doi: 10.1074/jbc.M404541200 (2004). [DOI] [PubMed] [Google Scholar]
  9. Sheridan J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818–821, doi: 10.1126/science.277.5327.818 (1997). [DOI] [PubMed] [Google Scholar]
  10. Kelley S. K. et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299, 31–38 (2001). [PubMed] [Google Scholar]
  11. Xiang H., Nguyen C. B., Kelley S. K., Dybdal N. & Escandon E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 32, 1230–1238, doi: 10.1124/dmd.104.000323 (2004). [DOI] [PubMed] [Google Scholar]
  12. Jain R. K. & Stylianopoulos T. Delivering nanomedicine to solid tumors. Nature reviews. Clinical oncology 7, 653–664, doi: 10.1038/nrclinonc.2010.139 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Agrahari V., Agrahari V. & Mitra A. K. Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities. Ther Deliv 7, 257–278, doi: 10.4155/tde-2015-0012 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mitchell M. J., Wayne E., Rana K., Schaffer C. B. & King M. R. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci USA 111, 930–935, doi: 10.1073/pnas.1316312111 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wayne E. C. et al. TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer. J Control Release 223, 215–223, doi: 10.1016/j.jconrel.2015.12.048 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Bae S. et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33, 1536–1546, doi: 10.1016/j.biomaterials.2011.10.050 (2012). [DOI] [PubMed] [Google Scholar]
  17. Muller N., Schneider B., Pfizenmaier K. & Wajant H. Superior serum half life of albumin tagged TNF ligands. Biochem Bioph Res Co 396, 793–799, doi: 10.1016/j.bbrc.2010.04.134 (2010). [DOI] [PubMed] [Google Scholar]
  18. Ishida T. et al. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release 105, 305–317, doi: 10.1016/j.jconrel.2005.04.003 (2005). [DOI] [PubMed] [Google Scholar]
  19. Xu H., Wang K. Q., Deng Y. H. & Chen D. W. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31, 4757–4763, doi: 10.1016/j.biomaterials.2010.02.049 (2010). [DOI] [PubMed] [Google Scholar]
  20. Jiang H. H. et al. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 32, 8529–8537, doi: 10.1016/j.biomaterials.2011.07.051 (2011). [DOI] [PubMed] [Google Scholar]
  21. Kim T. H. et al. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. J Control Release 150, 63–69, doi: 10.1016/j.jconrel.2010.10.037 (2011). [DOI] [PubMed] [Google Scholar]
  22. Guo L. R. et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release 154, 93–102, doi: 10.1016/j.jconrel.2011.05.008 (2011). [DOI] [PubMed] [Google Scholar]
  23. Lim S. M. et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 32, 3538–3546, doi: 10.1016/j.biomaterials.2011.01.054 (2011). [DOI] [PubMed] [Google Scholar]
  24. Chilkoti A. Genetically encoded stimulus responsive elastin-like polypeptides: Applications in drug delivery. Abstr Pap Am Chem S 243 (2012). [Google Scholar]
  25. McDaniel J. R. et al. Self-Assembly of Thermally Responsive Nanoparticles of a Genetically Encoded Peptide Polymer by Drug Conjugation. Angew Chem Int Edit 52, 1683–1687, doi: 10.1002/anie.201200899 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Dreher M. R. et al. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. J Am Chem Soc 130, 687–694, doi: 10.1021/Ja0764862 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. McDaniel J. R., Callahan D. J. & Chilkoti A. Drug delivery to solid tumors by elastin-like polypeptides. Adv Drug Deliver Rev 62, 1456–1467, doi: 10.1016/j.addr.2010.05.004 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. MacKay J. A. et al. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater 8, 993–999, doi: 10.1038/Nmat2569 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Cao L. et al. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol Cancer Ther 7, 851–861, doi: 10.1158/1535-7163.Mct-07-0533 (2008). [DOI] [PubMed] [Google Scholar]
  30. Huang K. et al. Fused hydrophobic elastin-like-peptides (ELP) enhance biological activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Protein Pept Lett 22, 1000–1006 (2015). [DOI] [PubMed] [Google Scholar]
  31. Meyer D. E. & Chilkoti A. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol 17, 1112–1115, doi: 10.1038/15100 (1999). [DOI] [PubMed] [Google Scholar]
  32. Zitzmann S., Ehemann V. & Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 62, 5139–5143 (2002). [PubMed] [Google Scholar]
  33. Gasparian M. E. et al. Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase. Biotechnol Lett 29, 1567–1573, doi: 10.1007/s10529-007-9446-y (2007). [DOI] [PubMed] [Google Scholar]
  34. Kang H., Sun A. Y., Shen Y. L. & Wei D. Z. Refolding and structural characteristic of TRAIL/Apo2L inclusion bodies from different specific growth rates of recombinant Escherichia coli. Biotechnol Progr 23, 286–292, doi: 10.1021/Bp060238c (2007). [DOI] [PubMed] [Google Scholar]
  35. Jiang J. et al. GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial. Eur J Pharmacol 740, 722–732, doi: 10.1016/j.ejphar.2014.06.002 (2014). [DOI] [PubMed] [Google Scholar]
  36. Ganten T. M. et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12, 2640–2646, doi: 10.1158/1078-0432.Ccr-05-2635 (2006). [DOI] [PubMed] [Google Scholar]
  37. Wang H. Z., Davis J. S. & Wu X. W. Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity. Mol Cancer Ther 13, 643–650, doi: 10.1158/1535-7163.Mct-13-0645 (2014). [DOI] [PubMed] [Google Scholar]
  38. Pan L. Q. et al. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Biomaterials 34, 9115–9123, doi: 10.1016/j.biomaterials.2013.08.020 (2013). [DOI] [PubMed] [Google Scholar]
  39. Kim T. H. et al. PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Control Release 162, 422–428, doi: 10.1016/j.jconrel.2012.07.021 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Byeon H. J. et al. Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. Acta biomaterialia 10, 142–150, doi: 10.1016/j.actbio.2013.08.046 (2014). [DOI] [PubMed] [Google Scholar]
  41. Younes A. et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin’s lymphoma. Brit J Cancer 103, 1783–1787, doi: 10.1038/sj.bjc.6605987 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Chae S. Y. et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 9, 1719–1729, doi: 10.1158/1535-7163.MCT-09-1076 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Jain R. K. & Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7, 653–664, doi: 10.1038/nrclinonc.2010.139 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. MacEwan S. R., Hassouneh W. & Chilkoti A. Non-chromatographic purification of recombinant elastin-like polypeptides and their fusions with peptides and proteins from Escherichia coli. Journal of visualized experiments: JoVE, doi: 10.3791/51583 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. MacEwan S. R. & Chilkoti A. Applications of elastin-like polypeptides in drug delivery. J Control Release 190, 314–330, doi: 10.1016/j.jconrel.2014.06.028 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Kim W., Brady C. & Chaikof E. L. Amphiphilic protein micelles for targeted in vivo imaging. Acta Biomater 8, 2476–2482, doi: 10.1016/j.actbio.2012.04.011 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. McDaniel J. R. et al. Noncanonical Self-Assembly of Highly Asymmetric Genetically Encoded Polypeptide Amphiphiles into Cylindrical Micelles. Nano Lett 14, 6590–6598, doi: 10.1021/Nl503221p (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Choi H. S. et al. Design considerations for tumour-targeted nanoparticles. Nature nanotechnology 5, 42–47, doi: 10.1038/nnano.2009.314 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Callahan D. J. et al. Triple stimulus-responsive polypeptide nanoparticles that enhance intratumoral spatial distribution. Nano Lett 12, 2165–2170, doi: 10.1021/nl300630c (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Meyer D. E. & Chilkoti A. Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system. Biomacromolecules 3, 357–367 (2002). [DOI] [PubMed] [Google Scholar]
  51. Meyer D. E. & Chilkoti A. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol 17, 1112–1115 (1999). [DOI] [PubMed] [Google Scholar]
  52. Zhang L. W. et al. Activatable Hyaluronic Acid Nanoparticle as a Theranostic Agent for Optical/Photoacoustic Image-Guided Photothermal Therapy. Acs Nano 8, 12250–12258, doi: 10.1021/Nn506130t (2014). [DOI] [PubMed] [Google Scholar]
  53. Liu L. S. et al. Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesions. Biomaterials 35, 8002–8014, doi: 10.1016/j.biomaterials.2014.05.081 (2014). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep41904-s1.doc (3.4MB, doc)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES